Scarica l'app Stockscreener
2.12
4.43%
0.09
Dopo l'orario di chiusura:
2.10
-0.02
-0.94%
Cytomx Therapeutics Inc Borsa (CTMX) Ultime notizie
What makes CytomX Therapeutics Inc. stock price move sharplyJuly 2025 Drop Watch & Risk Adjusted Swing Trade Ideas - beatles.ru
CytomX Therapeutics Earnings Call: Clinical Progress and Financial Strength - MSN
Is This the Dip to Buy in CytomX Therapeutics Inc.Breakout Watch & Expert Approved Trade Ideas - classian.co.kr
What institutional flow reveals about CytomX Therapeutics Inc.Buy Signal & Community Verified Watchlist Alerts - Newser
CytomX Therapeutics Inc. stock trend forecastGlobal Markets & Expert Curated Trade Setup Alerts - Newser
CytomX Therapeutics Inc. Stock Performance After Earnings: Historical InsightsPortfolio Gains Summary & AI Optimized Trading Strategy Guides - Newser
News impact scoring models applied to CytomX Therapeutics Inc.Weekly Trend Recap & Capital Efficient Trade Techniques - Newser
Intraday Charts Show Spike in CytomX Therapeutics Inc. ActivityGap Down & Advanced Swing Trade Entry Plans - sundaytimes.kr
Analyzing CytomX Therapeutics Inc. with multi timeframe chartsMarket Activity Recap & Technical Analysis for Trade Confirmation - Newser
Advanced analytics toolkit walkthrough for CytomX Therapeutics Inc.Gap Up & Free Technical Confirmation Trade Alerts - Newser
Is this a good reentry point in CytomX Therapeutics Inc.Portfolio Performance Summary & Weekly Watchlist of Top Performers - Newser
Identifying reversal signals in CytomX Therapeutics Inc.Weekly Profit Analysis & Weekly Market Pulse Alerts - Newser
Technical analysis overview for CytomX Therapeutics Inc. stockJuly 2025 Pullbacks & Long-Term Growth Plans - Newser
CytomX's High-Risk, High-Reward ADC Strategy: Can CX-2051 Overcome Safety Hurdles and Deliver Value? - AInvest
Published on: 2025-08-15 21:04:24 - sundaytimes.kr
CytomX to continue Phase I ADC trial despite patient death - Yahoo Finance
CytomX Therapeutics Soars 10.23% on Clinical Trial Progress - AInvest
Is CytomX Therapeutics Inc. stock poised for growth2025 Technical Overview & Community Consensus Picks - Newser
FMR LLC's Strategic Acquisition of CytomX Therapeutics Inc Shares Boosts Biotech Portfolio - AInvest
RSI Suggests Rebound May Be Near in CytomX Therapeutics Inc.July 2025 Intraday Action & AI Driven Stock Reports - metal.it
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2025 Earnings Call Transcript - MSN
Barclays sees ‘significant potential’ in CytomX’s CX-2051 despite safety event - MSN
Cancer patient dies in clinical trial, drugmaker's stock falls, but the study goes on - The Business Journals
CytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors - Barchart.com
Not Many Are Piling Into CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock Yet As It Plummets 26% - simplywall.st
Slammed 26% CytomX Therapeutics, Inc. (NASDAQ:CTMX) Screens Well Here But There Might Be A Catch - 富途牛牛
Is CytomX Therapeutics Inc. reversing from oversold territory2025 Key Highlights & Community Verified Swing Trade Signals - Newser
What is HC Wainwright’s Estimate for CTMX FY2026 Earnings? - Defense World
CytomX stock falls after reporting patient death in Phase 1 trial - Investing.com
Declining Stock and Solid Fundamentals: Is The Market Wrong About CytomX Therapeutics, Inc. (NASDAQ:CTMX)? - 富途牛牛
CytomX Therapeutics Updates on CX-2051 Phase 1 Study - TipRanks
CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study | C - GuruFocus
CytomX Therapeutics reports safety update in CX-2051 Phase 1 study - Investing.com Nigeria
CytomX Therapeutics provides update on CX-2051 Phase 1 study - MarketScreener
CytomX Therapeutics Provides Update On CX-2051 Phase 1 Study - TradingView
CytomX Cancer Drug Trial Continues Despite Patient Death, Phase 1 Data Expected Q1 2026 - Stock Titan
HC Wainwright Issues Pessimistic Outlook for CTMX Earnings - Defense World
Published on: 2025-08-13 07:49:54 - sundaytimes.kr
CytomX Therapeutics Reports Strong Financial Turnaround - TipRanks
CytomX Therapeutics (CTMX.O) Surges 11.9% — What’s Behind the Unusual Move? - AInvest
CytomX Therapeutics Inc. Inches Above Key Support — Safe to HoldMarket Momentum Signal Generator Shows Trends - beatles.ru
CytomX Therapeutics Reports Improved Financials, Net Income Reaches $23.4 Million - AInvest
CytomX Therapeutics (CTMX): Navigating a Financial Downturn While Advancing Groundbreaking Cancer Therapies - AInvest
CytomX Therapeutics: Updated Outlook For Late 2025 (NASDAQ:CTMX) - Seeking Alpha
CytomX Therapeutics shares fall 2.51% after-hours following Q2 2025 earnings call. - AInvest
Transcript : CytomX Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
CytomX Therapeutics (CTMX) Reports Break-Even Earnings for Q2 - NewsBreak: Local News & Alerts
Earnings call transcript: CytomX Q2 2025 results show revenue decline, stock dips - Investing.com
CytomX Therapeutics Inc (CTMX) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
CytomX Therapeutics Inc (CTMX) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
CytomX Therapeutics Inc (CTMX) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Decline - GuruFocus
0.94%
1.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):